Dr. Alex Pasteur

Board Member

Alex is a Partner with F-Prime Capital based in London. He has worked in healthcare investing since 2001. Alex focuses on investments in therapeutics and healthcare IT. His other portfolio includes/included Acacia Pharma Group (BRU: ACPH), Adaptimmune Therapeutics (NASDAQ: ADAP), Arvelle Therapeutics Ltd (acquired by Angelini Pharma), Castor (Ciwit B.V.), Genomics PLC, Orchard Therapeutics (NASDAQ: ORTX), Oviva AG, Owkin Inc., Peptone, and Shift Bioscience. Prior to joining F-Prime in 2012, Alex worked at MVM Life Science Partners LLP in the US and Europe.

Alex earned an M.A. in Natural Sciences from Cambridge University and a Ph.D. in Chemistry from Cambridge University.

Scroll to Top